Branded

JERUSALEM — Late-stage clinical data support the efficacy of an experimental drug under development by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis, the two companies said.

NEW YORK — Next year, the share of brand-name drugs paid by Medicare Part D beneficiaries will drop to 47.5%. The share of generics will drop to 72%, according to a report published Monday in The Wall Street Journal.

SILVER SPRING, Md. — The Food and Drug Administration is requiring Johnson & Johnson to use long-lasting ink in the labeling and dosage strength of an opioid painkiller patch it markets in order to make it easier to see.

PLANO, Texas — Research Now announced the launch of its Diabetes Panel, a collection of 336,000 deeply-profiled panelists in the United States and Canada who have been diagnosed with Type 1 diabetes, Type 2 diabetes, high blood pressure or obesity. Research Now's Healthcare Panels also include physicians, nurses, pharmacists, hospital executives and administrators.

DEERFIELD, Ill. — In preparation for flu season, actress Amanda Peet, ambassador of the UN Foundation's Shot@Life program, received her annual flu shot at Walgreens' flagship store in New York City to support its "Get a Shot, Give a Shot" campaign.

As a mother, actress and ambassador to the UN Foundation's Shot@Life program, Peet spoke about the importance of providing life-saving vaccinations to children in need across the globe. 

DUBLIN — Actavis has appointed the board of directors for the division it recently created as part of its acquisition of Ireland-based Warner Chilcott, the drug maker said.

Actavis, which announced the $8.5 billion purchase of Warner Chilcott, cleared the final regulatory hurdle to the acquisition Monday when the Irish High Court approved it. As part of the acquisition, it is changing Warner Chilcott's name to Actavis plc.

LAVAL, Quebec — Drug maker Valeant Pharmaceuticals International is joining an effort to oppose domestic violence, the company said Wednesday.

Valeant announced that it had formed a partnership with the National Coalition Against Domestic Violence to help raise awareness of the problem, with plans to donate a portion of sales from Medicis and Obagi products to the organization.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug developed by Takeda to treat major depressive disorder, the agency said.

The FDA announced the approval of Brintellix (vortioxetine) tablets for treating MDD in adults. The drug will be available in the 5-mg, 10-mg, 15-mg and 20-mg strengths.